LAVA Therapeutics N.V. LVTX
1.74 0.00 (+0.00%)
At closeNov 28, 2025, 4:00 PM EST
1.74 Day range 1.74
52-week range unavailable
- YTD
- +82.97%
- 1 year
- +8.75%
Analyst view
Consensus: buy
Buy
Price target (mean) 2.32 +33.5% upside
Now 1.74
- Target (low)
- 1.99
- Target (mean)
- 2.32
- Target (high)
- 2.98
Ratings (0m) 4 2 buy · 2 hold · 0 sell
- Strong buy1
- Buy1
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.2675 | -0.371 – -0.164 | -0.22099 | -21.0% | 2.40M | +637.2% | 2 |
| Next quarter | -0.3445 | -0.352 – -0.337 | -0.01842 | -1770.3% | 0 | -100.0% | 2 |
| Current year | -1.02 | -1.12 – -0.915 | -1.45 | +29.5% | 7.41M | +18.9% | 2 |
| Next year | -1.40 | -1.44 – -1.36 | -1.02 | -37.1% | 0 | -100.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 12, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Dec 11, 2024 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Aug 21, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Jun 28, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 21, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 19, 2021 | Jefferies | Initiated | — | Buy |
| Apr 19, 2021 | JP Morgan | Initiated | — | Overweight |
| Apr 19, 2021 | SVB Leerink | Initiated | — | Outperform |